Literature DB >> 12390190

Presence of Leishmania organisms in specific and non-specific skin lesions in HIV-infected individuals with visceral leishmaniasis.

Ricardo J Bosch1, Ana B Rodrigo, Purificación Sánchez, María V de Gálvez, Enrique Herrera.   

Abstract

BACKGROUND: Leishmania coinfection is frequently seen in human immunodeficiency virus (HIV)-infected patients in endemic areas, and from time to time the protozoan is detected in cutaneous biopsies.
OBJECTIVE: To establish the characteristics and possible ethiologic role of the presence of Leishmania in these lesions.
METHODS: We studied 12 cutaneous biopsies with Leishmania organisms from nine HIV-infected patients (seven men and two women) with visceral leishmaniasis, diagnosed by bone marrow examination, seen over a period of 9 years.
RESULTS: Based on clinical characteristics, evolution and response to anti-leishmanial treatment, cutaneous alterations were found to be related to the presence of the protozoan in six cases, whereas in the other six cases it was not considered responsible for the dermatological lesions (dermatofibroma, and lesions of psoriasis, Reiter's syndrome, bacillary angiomatosis, cryptococcosis and oral aphthae). Of note was the high prevalence of specific mucocutaneous manifestations, usually accompanied by intense pruritus, great variability, and a tendency to relapse after treatment stopped. On two occasions, detection of the protozoa in skin biopsies led to the diagnosis of a previously unsuspected visceral leishmaniasis.
CONCLUSIONS: Cutaneous detection of Leishmania is frequent in HIV-infected individuals with visceral leishmaniasis. Sometimes Leishmania is associated with changes attributable to other dermatological processes, and its presence does not imply a causative role. A clear relationship between the systemic process and the therapeutic response is necessary to demonstrate an ethiologic role.

Entities:  

Mesh:

Year:  2002        PMID: 12390190     DOI: 10.1046/j.1365-4362.2002.01610.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  6 in total

1.  Disseminated cutaneous leishmaniasis resembling post-kala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia.

Authors:  Tesfaye Gelanew; Zewdu Hurissa; Ermias Diro; Aysheshm Kassahun; Katrin Kuhls; Gabriele Schönian; Asrat Hailu
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Visceral leishmaniasis revealed by a squamous cell carcinoma in an HIV-1 infected patient.

Authors:  P Donati; G Paolino; C Panetta; L Muscardin; C Cota; M Giuliani
Journal:  Infection       Date:  2013-02-03       Impact factor: 3.553

Review 3.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 4.  PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.

Authors:  Eduard E Zijlstra
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

Review 5.  Leishmaniasis-HIV coinfection: current challenges.

Authors:  José Angelo Lauletta Lindoso; Mirella Alves Cunha; Igor Thiago Queiroz; Carlos Henrique Valente Moreira
Journal:  HIV AIDS (Auckl)       Date:  2016-10-07

6.  First Serological Study Revealing High Humoral Response and Evidence for Antigenic Heterogeneity in Leishmania donovani Induced CL in Sri Lanka.

Authors:  Bhagya Deepachandi; Sudath Weerasinghe; Samantha Ranasinghe; Thisira P Andrahennadi; Mahendra N Wickramanayake; Shantha Siri; Nadira Karunaweera; Vishvanath Chandrasekharan; Mitali Chatterjee; Preethi Soysa; Yamuna Siriwardana
Journal:  Biomed Res Int       Date:  2020-09-29       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.